Advertisement

Topics

FDA approves new treatment for chronic hepatitis C genotype 3 infections

09:44 EDT 24 Jul 2015 | FDA

The U.S. Food and Drug Administration today approved Daklinza (daclatasvir) for use with sofosbuvir to treat hepatitis C virus (HCV) genotype 3 infections. Daklinza is the first drug that has demonstrated safety and efficacy to treat genotype 3 HCV infections without the need for co-administration of interferon or ribavirin, two FDA-approved drugs also used to treat HCV infection.

Original Article: FDA approves new treatment for chronic hepatitis C genotype 3 infections

NEXT ARTICLE

More From BioPortfolio on "FDA approves new treatment for chronic hepatitis C genotype 3 infections"

Advertisement
Quick Search
Advertisement
Advertisement